Cristina Vazquez Guillamet1, Marin H Kollef. 1. aDivision of Pulmonary, Critical Care, and Sleep Medicine bDivision of Infectious Diseases, University of New Mexico School of Medicine, Albuquerque, New Mexico cDivision of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Abstract
PURPOSE OF REVIEW: To highlight the importance of escalating pathogen resistance in ventilator-associated pneumonia (VAP) along with diagnostic and treatment implications. RECENT FINDINGS: In a period of rising bacterial resistance, VAP remains an important infection occurring in critically ill patients. Risk factors for multidrug-resistant pathogens depend on both local epidemiology and host factors. New diagnostic techniques and antimicrobials can help with rapid bacterial identification and timely and appropriate treatment while avoiding emergence of bacterial resistance. SUMMARY: Clinicians should be aware of risk factors for multidrug-resistant pathogens causing VAP and also of particularities of diagnosis and treatment of this important clinical entity.
PURPOSE OF REVIEW: To highlight the importance of escalating pathogen resistance in ventilator-associated pneumonia (VAP) along with diagnostic and treatment implications. RECENT FINDINGS: In a period of rising bacterial resistance, VAP remains an important infection occurring in critically illpatients. Risk factors for multidrug-resistant pathogens depend on both local epidemiology and host factors. New diagnostic techniques and antimicrobials can help with rapid bacterial identification and timely and appropriate treatment while avoiding emergence of bacterial resistance. SUMMARY: Clinicians should be aware of risk factors for multidrug-resistant pathogens causing VAP and also of particularities of diagnosis and treatment of this important clinical entity.
Authors: Cristina Vazquez Guillamet; Rodrigo Vazquez; Jonas Noe; Scott T Micek; Marin H Kollef Journal: Medicine (Baltimore) Date: 2016-08 Impact factor: 1.889
Authors: Rami Sommerstein; Tobias M Merz; Sabine Berger; Julia G Kraemer; Jonas Marschall; Markus Hilty Journal: Antimicrob Resist Infect Control Date: 2019-05-22 Impact factor: 4.887
Authors: Josef Prazak; Luca G Valente; Manuela Iten; Lea Federer; Denis Grandgirard; Sara Soto; Gregory Resch; Stephen L Leib; Stephan M Jakob; Matthias Haenggi; David R Cameron; Yok-Ai Que Journal: J Infect Dis Date: 2022-04-19 Impact factor: 7.759